16th Annual Life Sciences Trade and Channel Strategies
Drug Channels
NOVEMBER 8, 2020
Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!
Pharmaceuticals Specialty Pharmacies Vaccine 
52 
16th Annual Life Sciences Trade and Channel Strategies
Drug Channels
OCTOBER 19, 2020
Gain Critical Insight from Industry Trailblazers During a Time of Transformative Change – Speakers will include : Bill Roth, Founding Partner, Blue Fin Group Rob Osborne, Vice President Pharma Trade Relations, Express Scripts, Accredo, CuraScript SD Ray Tancredi, RPh, MBA, CSP, Divisional Vice President, Specialty Pharmacy Development & Brand Rx/Vaccine (..)
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
Drug Channels
OCTOBER 10, 2023
I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business. and Section 6.4.3.
ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
The Pharma Data
APRIL 4, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Both tablet strengths are available via prescription through existing specialty pharmacy networks. FDA approval for mCSPC in September 2019.To
Let's personalize your content